Login / Signup

Enhancing prognostication and personalizing treatment of extranodal marginal zone lymphoma.

Juan Pablo AlderuccioIzidore S Lossos
Published in: Expert review of hematology (2023)
The lack of consistent genotyping profile in EMZL precludes the development of tissue and circulatory biomarkers for the diagnosis, risk stratification and monitoring of minimal residual disease. Furthermore, the biological heterogeneity observed in extranodal sites associated with overall limited genomic data prevents the testing of druggable pathways aiming for a personalized treatment approach. Future clinical trials should focus on EMZL considering the unique clinical characteristics in the eligibility criteria and response assessment to better inform efficacy of novel agents and delineate sequence of therapies.
Keyphrases
  • clinical trial
  • genome wide
  • mouse model
  • electronic health record
  • machine learning
  • single cell
  • gene expression
  • smoking cessation
  • replacement therapy
  • phase ii
  • double blind
  • current status
  • combination therapy